Thyas Co. Ltd. (“Thyas”; Kyoto, Japan; Representative Directors, Yasumichi Hitoshi and Ryosuke Gonotsubo) has announced it concluded a joint research agreement and a license agreement for an exclusive use of data and patents of clinical manufacturing methods of iPSC-derived CAR-transduced natural killer cells (“iCAR-NK”) with the Center for iPS Cell Research and Application, Kyoto University (“CiRA”; Kyoto, Japan; Director: Jun Takahashi), The CiRA Foundation (“CiRA_F”; Kyoto, Japan; Representative Director: Shinya Yamanaka), Kirin Holdings Company, Limited (“Kirin Holdings”; Tokyo, Japan; President and CEO: Yoshinori Isozaki).

Click here for more details.